Home    Corporate    Technology   Products   News    FAQ    Job Opportunities    Contact
   Food Safety    Environmental Sanitation    Veterinary Applications    Human Therapeutics
Intralytix is using its core bacteriophage technology to develop novel natural products for use in food processing, environmental clean-up, sanitation, consumer products, and problems of antibiotic resistance in human therapy.

Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Bacteriophages (bacteria-eater: from the Greek phago meaning “to eat” or “to develop at the expense of”) are the most abundant microorganisms on earth.  They are the natural enemies of bacteria.  Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for any antimicrobial.



  In the News

Health Canada approved the use of EcoShield™ as a processing aid for red meat in Canada
Health Canada approved the use of SalmoFresh™ as a processing aid for various foods in Canada, in all jurisdictions recognized by Health Canada for the purposes of the iLONO policy
National Food Service, Ministry of Health, Tel Aviv, Israel, issued "Guidelines: Use of Bacteriophages (bacteria killing viruses) in Food" (Ref: 70275202).
Intralytix Wins USDA Grant To Develop A Phage-Based Application To Protect Hatchery-Raised Oysters From The Bacterial Pathogen, Vibrio tubiashii
Intralytix Wins Regulatory Approval For Phage-Based Food Safety Product Effective Against Salmonella
Intralytix Signs Multiple Project Collaboration Agreement with Procter & Gamble
Intralytix Awarded Grant For Managing Salmonella in Food
Intralytix Completes Regulatory Clearance for Phage-Based E. coli Food Safety Technology
Intralytix Receives Follow-On Army Contract To Develop A Phage-Based Probiotic To Manage Shigella Infections
Intralytix's CSO Appointed Editor-In-Chief of New Phage Journal
Intralytix Receives FDA Regulatory Clearance for Phage-Based E. coli Technology
Intralytix Wins Army Grant To Develop A Phage-Based Probiotic To Manage Shigella Infections
Intralytix Receives a Phase I U.S. Army Grant for Phage-Based Product Development
Intralytix Wins Army Grant for Salmonella and Shigella Technology
Intralytix awarded patent by USPTO for Bacteriophage treatment of colonization by pathogen bacteria, including MRSA
Intralytix wins Phase III Army grant for E. Coli technology